Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Mach7 Technologies ( (AU:M7T) ).
Mach7 Technologies will release its Q2 FY26 results for the quarter ended 31 December 2025 on 30 January 2026 and will follow the announcement with an investor webinar hosted by CEO Teri Thomas and CFO Dan Lee. The session, open to the investment community and later available as a recording on the company’s investor relations site, underscores Mach7’s ongoing engagement with shareholders and market participants ahead of a key quarterly update for the medical imaging software specialist.
The most recent analyst rating on (AU:M7T) stock is a Hold with a A$0.60 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
More about Mach7 Technologies
Mach7 Technologies (ASX:M7T) is a medical imaging software provider that delivers advanced data management and diagnostic viewing solutions to healthcare organisations globally. Its flagship Enterprise Imaging Solution integrates a vendor neutral archive, the eUnity enterprise diagnostic viewer and workflow applications, enabling flexible, scalable imaging ecosystems for large health networks, national systems, independent provider groups and private radiology practices.
Average Trading Volume: 304,374
Technical Sentiment Signal: Buy
Current Market Cap: A$137.5M
For a thorough assessment of M7T stock, go to TipRanks’ Stock Analysis page.